The FDA Approved a Device and a Sentence. The Sentence Is About Other Molecules.
The label credits outcomes trials run on statins and monoclonal antibody PCSK9 inhibitors. LEROCHOL is neither, and has no outcomes trial of its own.
Access Read
Two TROP2 Conjugates Reached the Same Patients Ten Weeks Apart, and Payers Finally Have a Choice to Make
Until this summer every approved ADC held its indication alone. Two TROP2 conjugates now share one first-line population, and payers finally have a comparator.
CMS Projects: Fewer Losses and Bigger Savings. That Only Works If the Sick Are Removed.
CMS forecasts fewer disenrollments than CBO and higher savings. Both hold only if the people removed are the expensive ones, which means the sick.
Two Dominican High-Cost Lists Overlap by Only 44 Products. FOMAC Would Be a Third.
The country already covers this. Two schemes list 120 and 115 high-cost medicines, overlapping by 44. FOMAC would be a third list, starting at 13.
In Japan, Expanding a Label Is What Triggers the Price Cut
Dupixent, Nucala and Vyvdura were all cut after adding an indication. In Japan the trigger for a price cut is the drug reaching more patients.
Australia Cannot Settle Its Device Price Fight While the Service Sits Inside the Price
Both sides are fighting over a number nobody can produce. The evaluation went underneath them and named the reason: the service is inside the price.
Oman Is Offering Drug Manufacturers the One Thing Government Procurement Normally Destroys
Committing 30% of a health ministry’s requirement at agreed prices means deciding not to buy the cheapest product. Somebody is paying for that.
Korea Cleared Two Diagnostics on One Day, and Both Remove a Specialist
Nobody gained insurance access. Designation is the gate before the negotiation. The real story is that both lead technologies remove a specialist.
The MHRA Authorised Two Obesity Drugs in Two Days. Neither Is on the NHS.
Two MHRA authorisations in two days. One drug is too common to fund, the other too rare to prioritise. Neither is on the NHS.
CMS Opened a Same-Day Coverage Lane for Devices and Closed the Payment Route Underneath It
CMS Opened a Same-Day Coverage Lane for Devices and Closed the Payment Route Underneath It